MAP2K7 and central nervous system cancer: Furthermore, successful treatment of gliomas harboring BRAFV600E mutation with BRAF/MEK-inhibitors—dabrafenib plus trametinib—has been reported, with objective response rates of 33% in high-grade gliomas [20,21].